YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer

被引：0
|
作者：
Lei Wang
Quanren Wang
Piaopiao Xu
Li Fu
Yun Li
Haoyu Fu
Haitian Quan
Liguang Lou
机构：
[1] Chinese Academy of Sciences,Shanghai Institute of Materia Medica
来源：
British Journal of Cancer | 2020年 / 123卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1000 / 1011
页数：11
相关论文
共 50 条
  • [21] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
    Ponde, Noam
    Ameye, Lieveke
    Lambertini, Matteo
    Paesmans, Marianne
    Piccart, Martine
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 65 - 73
  • [23] Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
    Sabbaghi, Mohammad A.
    Gil-Gomez, Gabriel
    Guardia, Cristina
    Servitja, Sonia
    Arpi, Oriol
    Garcia-Alonso, Sara
    Menendez, Silvia
    Arumi-Uria, Montserrat
    Serrano, Laia
    Salido, Marta
    Muntasell, Aura
    Martinez-Garcia, Maria
    Zazo, Sandra
    Chamizo, Cristina
    Gonzalez-Alonso, Paula
    Madoz-Gurpide, Juan
    Eroles, Pilar
    Arribas, Joaquin
    Tusquets, Ignasi
    Lluch, Ana
    Pandiella, Atanasio
    Rojo, Federico
    Rovira, Ana
    Albanell, Joan
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 7006 - 7019
  • [24] Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
    Matteo Allegretti
    Alessandra Fabi
    Elena Giordani
    Cristiana Ercolani
    Paolo Romania
    Cecilia Nisticò
    Simona Gasparro
    Vittoria Barberi
    Maria Ciolina
    Edoardo Pescarmona
    Diana Giannarelli
    Gennaro Ciliberto
    Francesco Cognetti
    Patrizio Giacomini
    Molecular Cancer, 20
  • [25] Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
    Allegretti, Matteo
    Fabi, Alessandra
    Giordani, Elena
    Ercolani, Cristiana
    Romania, Paolo
    Nistico, Cecilia
    Gasparro, Simona
    Barberi, Vittoria
    Ciolina, Maria
    Pescarmona, Edoardo
    Giannarelli, Diana
    Ciliberto, Gennaro
    Cognetti, Francesco
    Giacomini, Patrizio
    MOLECULAR CANCER, 2021, 20 (01)
  • [26] Trastuzumab Emtansine (T-DM1): No radiosensitizing effect in vitro on HER2-positive breast cancer cells (study in vitro)
    Mignot, Fabien
    Kirova, Youlia
    Verrelle, Pierre
    Teulade-Fichou, Marie-Paule
    Megnin-Chanet, Frederique
    CANCER RESEARCH, 2020, 80 (04)
  • [27] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
    Sandhya Girish
    Manish Gupta
    Bei Wang
    Dan Lu
    Ian E. Krop
    Charles L. Vogel
    Howard A. Burris III
    Patricia M. LoRusso
    Joo-Hee Yi
    Ola Saad
    Barbara Tong
    Yu-Waye Chu
    Scott Holden
    Amita Joshi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1229 - 1240
  • [28] Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    ONCOLOGY REPORTS, 2013, 30 (03) : 1087 - 1093
  • [29] The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
    Delgado, J.
    Vleminckx, C.
    Sarac, S.
    Sosa, A.
    Bergh, J.
    Giuliani, R.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2021, 6 (02)
  • [30] Potentiation of trastuzumab emtansine (T-DM1)-driven antitumor activity by pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345